Immunovant, Inc.
IMVTNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | −$505.6M | −$413.8M | −$259.3M | −$211.0M | −$156.7M | −$107.4M |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M | $412.5M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M | $21.0M |
| Equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M | $391.5M |
| EPS (diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 |
| Shares out. | 205.3M | 170.9M | 146.1M | 130.4M | 116.5M | 98.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2026- Operating margin
- —
- Net margin
- —
- Return on equity
- −59.3%
- Return on assets
- −52.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 10.9%
- Debt / equity
- 0.12×
- Book value / share
- $4.15
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2026- Accruals / assets
- −10.3%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2025-01-10Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
- Phase 2Active Not Recruitingreadout ~2026-01To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
- Phase 2Active Not Recruitingreadout ~2026-10A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
- Phase 2Recruitingreadout ~2027-05A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Phase 2Active Not Recruitingreadout ~2027-09A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
- Phase 3Recruitingreadout ~2027-12Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Phase 2Recruitingreadout ~2028-06A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- Phase 2Recruitingreadout ~2028-07Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Roivant Sciences Ltd.Activist (13D)Dec 12, 2025
- Fmr LlcPassive (13G)Nov 5, 2025
- Deep Track Capital, LpPassive (13G)Mar 26, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 20.4M | 16.4 | +9.6% |
| Apr 30, 2026 | 18.6M | 10.5 | -4.7% |
| Apr 15, 2026 | 19.5M | 13.8 | +5.8% |
| Mar 31, 2026 | 18.4M | 12.4 | +11.3% |
| Mar 13, 2026 | 16.6M | 16.1 | -1.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 20, 2026
- Results of operationsFeb 6, 2026
- Other material eventDec 12, 2025
- Other material eventDec 11, 2025
- Director / officer changeNov 21, 2025
- Results of operationsNov 10, 2025
- Regulation FD disclosure · Other material eventSep 3, 2025
- Shareholder voteAug 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.